mRNA-3927 / Moderna  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
mRNA-3927 / Moderna
2019-003529-36: A clinical study to evaluate the medicinal product in Patients with Propionic Acidemia

Not yet recruiting
1/2
36
Europe
mRNA-3927, Injection
ModernaTX, Inc, ModernaTX, Inc.
Propionic Acidemia- Propionic acidemia is an autosomal recessive disorder caused by loss-of-function mutations in PCCA or PCCB (and in rare instances, mutations in both PCCA and PCCB), resulting in the loss of enzymatic activity of the mitochondrial complex PCC, Deficiency of PCCA and PCCB, Body processes [G] - Metabolic Phenomena [G03]
 
 
mRNA-3927-P101, NCT04159103: Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

Recruiting
1/2
68
Europe, Canada, US
mRNA-3927
ModernaTX, Inc.
Propionic Acidemia
03/25
01/27
NCT05130437: A Long-Term Extension Study to Evaluate the Safety and Clinical Activity of mRNA-3927

Recruiting
1/2
36
Europe, Canada, US
mRNA-3927
ModernaTX, Inc.
Propionic Acidemia
12/29
12/31

Download Options